Blog Archives

05/22/2014

Biomarkers Enhance Astra Zeneca's Clinical Trial Successes

Tags: , ,

Biomarker data from Astra Zeneca demonstrates that biomarkers enhance success in every aspect (safety, dosing, efficacy, patient selection) of every state of the drug development process.

Continue Reading


06/14/2013

Blood, Sweat, and Robots

Tags: , , , , ,

Bill Malone wrote a great article for Clinical laboratory News (American Assoc for Clinical Chemistry) that goes straight to the heart of the folklore and  myth surrounding the use of automation in laboratories.  Check out “Blood, Sweat, and Robots.”

Continue Reading


05/07/2012

Assay Automation Ability - Lyophilized reagents for in vitro whole blood assays

Tags: , , , , , , ,

The need to implement robust biomarkers in clinical trials has never been greater, and such efforts can be easily compromised by reagent instability or simple human error during assay set-up. Many biotechnology and pharmaceutical companies are introducing efforts to conduct biomarker studies under more rigorous settings, and the use of plates or tubes pre-loaded with stimulation or staining reagents could be of value for studies that involve flow cytometry.
The value of this approach is that it lends itself to assay automation easily and safeguards against omission or erroneous addition of bulk liquid formulations of PMA and ionomycin to the reaction vessel (i.e., plate or tube) and also lends itself to extended stability/shelf-life of these reagents. On the basis of this initial success, we plan to expand our evaluation of lyophilized reagents so that they can be incorporated into our clinical biomarker campaigns as appropriate.

Continue Reading


01/10/2011

Validation of Cell-Based Assays in the GLP Setting

Tags: , , , , , ,

Readers gain an understanding of the details and the high level considerations of assay qualification for difficult cell-based assays. The level of optimization described for cell-based assays lends itself to biomarker assay automation which can be used for biomarker qualification and validation studies to the satisfaction of the FDA, EMEA, and other regulatory agencies.
Cell-based assay platforms covered are flow cytometry, intracellular cytokine ICS, immunophenotyping, elispot, IHC, cylex, neutralization bioassays, and endpoint assays.

Continue Reading